Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. ( SANA ) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Morgan Stanley, Research Division Great. Hello everyone. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. And with that, I'm happy to introduce Steve Harr, CEO of Sana Biotechnology. Thank you very much for joining me today.

Steven Harr President, CEO & Director Max, thanks for having us. I appreciate it.

Maxwell Skor Morgan Stanley, Research Division So, maybe just to get started. If you -- we'll give you the stage, introduce Sana's story, maybe set up recent progress, and what we should focus on going into the end of the year?

Steven Harr President, CEO & Director Sure. I'm sure everybody here recognizes we'll make forward-looking statements, and like you, I have my own little risk factor. Please read our 10-Q for looking at those risk factors. Now, we started the company around the idea that one of the most important transformations that will occur in medicine over the coming 20 years or so is the ability to engineer cells. And we wanted to do this in a way that allowed us to go after diseases that are highly prevalent with scalable platforms that could access patients broadly. And we chose to go after two problems. I am excited to say shortly we should be getting going on studies for them and really understanding their impact on human health. So, first one is if you transplant someone else's cells into your body, your body will see them as foreign and try to reject them or